종양학 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Oncology Market reached USD 320.3 billion in 2024 and is projected to grow at a CAGR of 10.8% from 2025 to 2034. Oncology, as a medical specialty, focuses on preventing, diagnosing, and treating cancer through a wide array of strategies, including surgical procedures, chemotherapy, radiotherapy, targeted therapies, and immunotherapy. Advances in oncology research aim to uncover the underlying causes and progression of cancer, driving the development of innovative treatments and improving patient outcomes.

The market is divided into cancer diagnostics and cancer treatment. Cancer diagnostics include imaging, biopsies, tumor biomarker tests, liquid biopsies, immunohistochemistry, and in situ hybridization. Meanwhile, the cancer treatment segment covers chemotherapy, targeted therapies, immunotherapy, hormonal therapy, and other interventions. In 2024, the cancer treatment segment held the largest market share at 54.6%, supported by a rising global cancer burden. This increase is attributed to aging populations, changing lifestyles, and environmental factors. Smoking, poor diets, physical inactivity, and exposure to pollutants are key contributors to the increasing incidence of cancer worldwide.

The market is further categorized by cancer type, including breast, lung, prostate, colorectal, gastric, liver, esophageal, and other cancers. Among these, breast cancer remains a leading segment in terms of revenue, fueled by its rising prevalence and growing focus on early detection and treatment advancements. Contributing factors include genetic predisposition, aging demographics, and shifting lifestyle patterns. Substantial investments in cancer research and healthcare infrastructure, particularly in emerging markets, are further improving access to advanced diagnostics and therapies. These efforts are accelerating market growth and enhancing patient care globally.

U.S. oncology market is poised for substantial growth, driven by the rising incidence of cancer cases. Factors such as an aging population and lifestyle risks are placing significant demands on healthcare systems, fueling the need for advanced treatments and diagnostic technologies. The growing burden of cancer is encouraging pharmaceutical companies, hospitals, and research institutions to innovate and develop more effective therapies, diagnostics, and support services.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of cancer globally
    • 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
    • 3.2.1.3 Growing number of diagnostic laboratories in developing countries
    • 3.2.1.4 Technological advancements in developed countries
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High capital investment coupled with high cost associated with diagnostic imaging system
    • 3.2.2.2 High risk of side effects associated with cancer treatment and risks associated with CT scanners
    • 3.2.2.3 Dearth of well-skilled and trained oncologists and radiologists
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Diagnostics and Treatment, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Cancer diagnostics
  • 5.2.1 Tumor biomarkers test
  • 5.2.2 Imaging
  • 5.2.3 Biopsy
  • 5.2.4 Liquid biopsy
  • 5.2.5 Immunohistochemistry
  • 5.2.6 In situ hybridization
• 5.3 Cancer treatment
  • 5.3.1 Chemotherapy
  • 5.3.2 Targeted therapy
  • 5.3.3 Immunotherapy
  • 5.3.4 Hormonal therapy
  • 5.3.5 Other cancer treatments

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Prostate cancer
• 6.4 Colon and rectal cancer
• 6.5 Gastric cancer
• 6.6 Esophageal cancer
• 6.7 Liver cancer
• 6.8 Breast cancer
• 6.9 Other cancer types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Diagnostic imaging centers
• 7.5 Academia
• 7.6 Specialty clinics
• 7.7 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Poland
  • 8.3.7 Switzerland
  • 8.3.8 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Thailand
  • 8.4.7 Indonesia
  • 8.4.8 Vietnam
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Colombia
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Israel

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Amgen
• 9.3 AstraZeneca
• 9.4 Bristol-Myers Squibb Company
• 9.5 Eli Lilly and Company
• 9.6 GE HealthCare Technologies
• 9.7 Gilead Sciences
• 9.8 GlaxoSmithKline
• 9.9 Johnson & Johnson
• 9.10 Merck & Co
• 9.11 Novartis
• 9.12 Pfizer
• 9.13 F. Hoffmann-La Roche
• 9.14 Sanofi
• 9.15 Takeda Pharmaceutical Company Limited